View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 24, 2016

Formula maker Biostime finds cheer in namesake brand

Biostime International Holdings, the Hong Kong-listed infant formula maker, has reported higher nine-month revenue, as sales from vitamins arm Swisse offset pressure on its formula business.

By Dean Best

Biostime International Holdings, the Hong Kong-listed infant formula maker, has reported higher nine-month revenue, as sales from vitamins arm Swisse offset pressure on its formula business.

The company posted revenue of CNY4.68bn (US$675.9m) for the nine months to the end of September, up from CNY4.49bn a year earlier.

However, Biostime said revenue from its baby care and nutrition division fell 3.3% amid a “highly competitive” infant formula market in China.

Biostime said the lower revenue from the division was “mainly attributable” to a decline in sales of its “mid-tier” Adimil infant formula brand. By contrast, revenue from the company’s Biostime-branded formula rose 8.8%.

Citing Nielsen data, Biostime said the company accounted for 6% of infant formula sales in China during the period, compared to 5.9% a year earlier.

Revenue from Swisse, which Biostime acquired in September 2015, rose 13.3%.

Biostime did not provide figures on profits for the nine-month period.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The industry's most comprehensive news and information delivered every other month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Just Food